June 4, 2009 — The latest results from the European First Episode Schizophrenia Trial (EUFEST) show that when it comes to improving cognition in patients with schizophrenia, there is little difference ...

SCOTTSDALE, Arizona ― Second-generation antipsychotics (SGAs) differ with regard to efficacy and side effect profiles for the treatment of first-episode psychosis, according to the results of a new ...

Schizophrenia medication falls under two main categories: older, first-generation, or "typical" antipsychotics and newer drugs for schizophrenia known as second-generation or "atypical" antipsychotics ...

While any patients taking an anti-dopaminergic agent may develop tardive dyskinesia (TD) -- a movement disorder hallmarked by abnormal and involuntary tics of the face, trunk, and limbs -- older ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Teva announces positive real-world outcomes for UZEDY® and TEV-'749 in schizophrenia treatment, highlighting improved adherence and reduced hospital visits. Teva Pharmaceuticals has announced positive ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Second-generation antipsychotics (SGAs) are essential for managing serious mental health conditions, but they can significantly increase risks for metabolic syndrome, diabetes, and heart disease.